In this video, Dr. Brian G.M. Durie explains why MRD-negative status and MRD-positive status are not clear indicators for next steps in a myeloma patient’s treatment.

BOTTOM LINE:
MRD-testing is not yet recommended for routine testing, yet the results can be reassuring to patients.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org.

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
CAR T-cell Therapy
Next Post
Role of Mass Spectrometry

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.